αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models
9.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-18 03:45
摘要：
αTIGIT-IL2 is an innovative immunocytokine designed to enhance antitumor immunity by targeting regulatory T cells (Tregs) in the tumor microenvironment. It promotes Treg fragility, leading to improved activation of CD8+ T cells and neutrophils, thereby facilitating tumor regression. This approach shows significant promise in overcoming resistance to immunotherapy, particularly in aggressive triple-negative breast cancer (TNBC) models. The findings suggest that αTIGIT-IL2 could be a valuable addition to cancer immunotherapy strategies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
1.0分
关键证据
αTIGIT-IL2 exhibits effective tumor control in both ICB treatment-sensitive and -resistant mouse models.
The combination of αTIGIT-IL2 and PD-1 blocker could eliminate triple-negative breast cancer tumors resistant to immune checkpoint blockade therapy.
The study provides a basis for developing a new generation of immunocytokines that target Treg cells.
真实性检查
否
AI评分总结
αTIGIT-IL2 is an innovative immunocytokine designed to enhance antitumor immunity by targeting regulatory T cells (Tregs) in the tumor microenvironment. It promotes Treg fragility, leading to improved activation of CD8+ T cells and neutrophils, thereby facilitating tumor regression. This approach shows significant promise in overcoming resistance to immunotherapy, particularly in aggressive triple-negative breast cancer (TNBC) models. The findings suggest that αTIGIT-IL2 could be a valuable addition to cancer immunotherapy strategies.